539561
SUPHA
Start SIP
Invest Now
Start SIP in SUPHA
Performance
- Low
- ₹1
- High
- ₹1
- 52 Week Low
- ₹1
- 52 Week High
- ₹3
- Open Price₹1
- Previous Close₹1
- Volume2,360,177
- 50 DMA₹0.93
- 100 DMA₹1.08
- 200 DMA₹1.69
Investment Returns
- Over 1 Month + 13.75%
- Over 3 Month -35.46%
- Over 6 Month -31.58%
- Over 1 Year -65.53%
Smart Investing Starts Here Start SIP with Supha Pharmachem for Steady Growth!
Supha Pharmachem Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- -37
- PEG Ratio
- 0.3
- Market Cap Cr
- 80
- P/B Ratio
- 0.9
- Average True Range
- 0.04
- EPS
- -
- Dividend Yield
- 0
- MACD Signal
- 0
- RSI
- 57.69
- MFI
- 55.84
Supha Pharmachem Financials
Supha Pharmachem Technicals
EMA & SMA
Current Price
₹0.91
+
0.01
(1.11%)
- Bearish Moving Average 8
- Bullish Moving Average 8
- 20 Day
- ₹0.88
- 50 Day
- ₹0.93
- 100 Day
- ₹1.08
- 200 Day
- ₹1.69
Resistance and Support
0.91
- R3 0.95
- R2 0.94
- R1 0.92
- S1 0.89
- S2 0.88
- S3 0.86
Supha Pharmachem Corporate Actions - Bonus, Splits, Dividends
| Date | Purpose | Remarks |
|---|---|---|
| 2026-02-14 | Quarterly Results | |
| 2025-11-14 | Quarterly Results | |
| 2025-09-22 | Rights Issue & Others | To consider 1. Increase in Authorised Capital. to consider 1. Letter of Offer for the proposed Rights Issue of 49,19,04,000 Equity Shares of Re. 1/- each, aggregating to 4919.04 lakhs for shareholders. 2. Other business matters. |
| 2025-08-04 | Quarterly Results | |
| 2025-05-30 | Audited Results |
Supha Pharmachem F&O
About Supha Pharmachem
- NSE Symbol
- SUPHA
- BSE Symbol
- 539561
- ISIN
- INE549S01036
Similar Stocks to Supha Pharmachem
Supha Pharmachem FAQs
Supha Pharmachem share price is ₹0 As on 14 February, 2026 | 06:35
The Market Cap of Supha Pharmachem is ₹80.3 Cr As on 14 February, 2026 | 06:35
The P/E ratio of Supha Pharmachem is -37 As on 14 February, 2026 | 06:35
The PB ratio of Supha Pharmachem is 0.9 As on 14 February, 2026 | 06:35
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.